Oral malodor reduction

Oral malodor reduction is a therapeutic objective aimed at mitigating halitosis, a condition where unpleasant odors are emitted during exhalation. This process is not a single molecular target but a clinical endpoint involving the management of volatile sulfur compounds (VSCs), such as hydrogen sulfide and methyl mercaptan, which are produced by the microbial degradation of sulfur-containing amino acids in the oral cavity [1][2]. The primary biological drivers are anaerobic Gram-negative bacteria, including Porphyromonas gingivalis and Prevotella intermedia, which colonize the tongue dorsum and periodontal pockets [3]. Drugs and oral care agents interact with this process by reducing bacterial load through antiseptic action or by chemically binding to VSCs to prevent their volatilization [4]. For example, zinc salts are widely used because they exhibit a high affinity for sulfur, converting odorous gases into stable, non-volatile metal sulfides [5]. Because 'oral malodor reduction' describes a physiological outcome rather than a specific protein, enzyme, or receptor, it is classified as a therapeutic indication or biological process rather than a discrete molecular target.

Other names

Halitosis controlBreath fresheningTreatment of bad breathReduction of volatile sulfur compounds

Oral malodor reduction is achieved via three primary mechanisms: the antimicrobial elimination of Gram-negative anaerobic bacteria (e.g., using Chlorhexidine or Cetylpyridinium chloride), the chemical neutralization of volatile sulfur compounds (VSCs) into non-volatile salts (e.g., using Zinc ions), and the oxidation of odorous compounds into non-odorous forms (e.g., using Chlorine dioxide or Hydrogen peroxide).